Hydron; 2-[4-[3-[2-(trifluoromethyl)-9-thioxanthenylidene]propyl]-1-piperazinyl]ethanol; dichloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻喃类
• 英文名称: Hydron; 2-[4-[3-[2-(trifluoromethyl)-9-thioxanthenylidene]propyl]-1-piperazinyl]ethanol; dichloride
• 英文别名: hydron;2-[4-[3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol;dichloride
• 化学式: C23H27Cl2F3N2OS
• 分子量: 507.4
• InChiKey: IOVDQEIIMOZNNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.45
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  52
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• [EN] PROCESS FOR THE PREPARATION OF Z-FLUPENTIXOL<br/>[FR] PROCEDE DE PREPARATION DE Z-FLUPENTIXOL
  申请人：LABORATORIO CHIMICO INT SPA

  公开号：WO2005037820A1

  公开（公告）日：2005-04-28

  The present invention relates to a process for the separation of flupentixol isomers, particularly, a process for the preparation of Z-flupentixol and the decanoate ester and novel synthetic intermediates thereof.

  本发明涉及一种用于分离氟哌替醇异构体的方法，特别是用于制备Z-氟哌替醇和癸酸酯及其新型合成中间体的方法。
• Neuroprotective agents
  申请人：——

  公开号：US20040063612A1

  公开（公告）日：2004-04-01

  The present invention relates to methods of treating neurodegenerative diseases with the neuroprotective agents of Formulas I-IV and XII and the other compounds described herein. The neuroprotective agents inhibit nitric oxide synthase enzymes and in particular nitric oxide synthase III (NOS III) and can be used to treat Alzheimer's disease.

  本发明涉及使用公式I-IV和XII以及本文中描述的其他化合物的神经保护剂治疗神经退行性疾病的方法。这些神经保护剂抑制一氧化氮合酶酶和特别是一氧化氮合酶III（NOS III），可用于治疗阿尔茨海默病。
• Small molecule toll-like receptor (TLR) antagonists
  申请人：Lipford B. Grayson

  公开号：US20050119273A1

  公开（公告）日：2005-06-02

  The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.

  本发明提供了用于调节通过Toll样受体信号传导的方法和组合物。该方法涉及使用含有至少两个环的核心结构的小分子与表达TLR的细胞接触。其中某些化合物是4-主氨基喹啉。许多化合物和方法特别适用于抑制涉及至少一个TLR9、TLR8、TLR7和TLR3的免疫刺激。该方法可用于治疗自身免疫、炎症、过敏、哮喘、移植排斥、移植物抗宿主病、感染、败血症、癌症和免疫缺陷。
• IDENTIFICATION OF STRUCTURALLY SIMILAR SMALL MOLECULES THAT ENHANCE THERAPEUTIC EXON SKIPPING
  申请人：The Regents of the University of California

  公开号：US20160257952A1

  公开（公告）日：2016-09-08

  This invention relates, e.g., to a method for enhancing exon skipping in a pre-mRNA of interest, comprising contacting the pre-mRNA with an effective amount of a compound such as, for example, Perphenazine, Flupentixol DiHCl, Zuclopenthixol or Corynanthine HCl, or a compound which shares a similar 2-D structure and activity level with one of these compounds, or a pharmaceutically acceptable salt, hydrate, solvate, or isomer of the compound, and, optionally, with an antisense oligonucleotide that is specific for a splicing sequence in the pre-mRNA Methods for treating Duchenne muscular dystrophy (DMD) are disclosed.

  本发明涉及一种增强感兴趣的前mRNA的外显子跳跃的方法，包括将前mRNA与有效量的化合物接触，例如Perphenazine、Flupentixol DiHCl、Zuclopenthixol或Corynanthine HCl，或具有类似2-D结构和活性水平的化合物，或化合物的药学上可接受的盐，水合物，溶剂化物或异构体，以及选择性针对前mRNA中剪接序列的反义寡核苷酸（如果需要）。还公开了治疗杜氏肌肉萎缩症（DMD）的方法。